CYCN Cyclerion Therapeutics, Inc.

Nasdaq cyclerion.com


$ 2.15 $ -0.09 (-4.02 %)    

Tuesday, 21-Oct-2025 15:59:53 EDT
QQQ $ 610.75 $ -0.12 (-0.02 %)
DIA $ 469.53 $ 2.06 (0.44 %)
SPY $ 671.17 $ -0.23 (-0.03 %)
TLT $ 92.00 $ 0.03 (0.03 %)
GLD $ 379.87 $ -8.85 (-2.29 %)
$ 2.2
$ 2.24
$ 2.15 x 1,015
$ 2.28 x 6
$ 2.15 - $ 2.24
$ 1.27 - $ 9.47
48,924
na
7.34M
$ 1.24
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 03-04-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-05-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 07-28-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-22-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 07-29-2021 06-30-2021 10-Q
18 04-30-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-03-2020 06-30-2020 10-Q
22 05-04-2020 03-31-2020 10-Q
23 03-12-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-12-2019 06-30-2019 10-Q
26 05-13-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outst...

Core News & Articles

Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their ...

 cyclerion-therapeutics-says-under-license-agreement-mit-eligible-for-up-to-44m-in-milestone-payments

-SEC Filing

 cyclerion-announces-license-agreement-with-mit-to-relaunch-advancing-phase-2ready-treatment-for-resistant-depression

– Cyclerion Relaunches, Advancing a Phase 2–Ready Program for Millions Living with Treatment-Resistant Depression Through MIT L...

 cyclerion-therapeutics-q2-eps-011-up-from-053-yoy-sales-9600k

Cyclerion Therapeutics (NASDAQ:CYCN) reported quarterly losses of $(0.11) per share. This is a 79.25 percent increase over loss...

 cyclerion-therapeutics-has-received-a-notice-of-allowance-for-a-us-patent-titled-processes-and-intermediates-for-the-preparation-of-soluble-guanylate-cyclase-stimulators

https://patentcenter.uspto.gov/applications/18671182/ifw/docs

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION